Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Beats Estimates By $0.03 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) posted its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.03, Zacks reports.

Here are the key takeaways from Eupraxia Pharmaceuticals’ conference call:

• Eupraxia says its Diffusphere platform can deliver fluticasone locally with one endoscopic injection, targeting roughly a year of treatment. In open-label EoE studies, the company reports clinical remission in 80% of patients at six months and 64% at 52 weeks; these results have not yet been confirmed against placebo.
• A Phase IIb interim readout is expected to include six-month placebo comparisons across symptoms, histology, endoscopic findings and safety, plus 52-week durability data. The interim analysis is not powered for statistical significance, so the company will look for evidence of separation from placebo; the completed trial is larger, with 40 patients per arm.
• Management described a substantial and growing U.S. EoE population, citing estimates of 500,000–600,000 patients, and highlighted challenges with daily oral therapies, including administration demands and candidiasis. The company argues that a treatment given during an already recommended annual endoscopy could improve adherence.
• The CEO said the company has seen no injection-related complications across about 3,000 injections and no candidiasis to date, though larger controlled trials will be needed to establish the safety profile. Management also pointed to possible expansion into benign esophageal strictures and, later, Crohn’s disease, while targeting an EoE Phase III start in mid-2027.
• Management believes the procedure could fit gastroenterologists’ existing practices and be reimbursed through the medical benefit, potentially supporting physician adoption. These commercial and reimbursement assumptions have yet to be validated in the market.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX opened at $8.06 on Thursday. Eupraxia Pharmaceuticals has a twelve month low of $5.63 and a twelve month high of $9.32. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02. The stock’s 50-day simple moving average is $7.62 and its 200 day simple moving average is $7.25. The firm has a market capitalization of $541.97 million, a PE ratio of -7.60 and a beta of 1.04.

Analyst Ratings Changes

Several brokerages have recently commented on EPRX. Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday. Stifel Nicolaus set a $25.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Oppenheimer reissued an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, October 20th. HC Wainwright boosted their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Royal Bank Of Canada assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $14.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.